SCHEMBL1796331

SCHEMBL1796331

C1CC2(CN1)CNC2

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27150426 0.94 TSHR (0.39)
SCHEMBL16877361 0.94 TSHR (0.39)
SCHEMBL5423967 0.93 TSHR (0.41)
SCHEMBL473625 0.89
SCHEMBL5429962 0.87
SCHEMBL625429 0.86
SCHEMBL343237 0.86
SCHEMBL303389 0.86 TSHR (0.41)
Bromide SCHEMBL29750142 0.83
Hydrochloric Acid SCHEMBL15537634 0.83

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 835 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260109702-A1 NOVEL GSPT PROTEIN DEGRADER AND APPLICATION THEREOF GENOSCO INC (US) 2026-04-23 US claimed
EP-4695256-A2 ERBB2 INHIBITORS Cogent Biosciences, Inc. (US) 2026-02-18 EP claimed
EP-4688792-A1 KRAS INHIBITORS Eli Lilly and Company (US) 2026-02-11 EP claimed
EP-4688784-A1 KRAS INHIBITORS Eli Lilly and Company (US) 2026-02-11 EP claimed
EP-4665718-A1 SMALL MOLECULES AS MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS, COMPOSITIONS AND USE THEREOF Apogee Pharmaceuticals, Inc. (CA) 2025-12-24 EP claimed
EP-4658661-A1 MACROCYCLIC AMINOPYRIDINE COMPOUNDS AS EGFR INHIBITORS Yuhan Corporation (KR) 2025-12-10 EP claimed
US-20250263412-A1 NON-HYDROXAMATE HDAC6 INHIBITORS AND RELATED METHODS OF USE THE REGENTS OF THE UNIVERSITY OF MICHIGAN 2025-08-21 US claimed
US-12378231-B2 Small molecules as monoacylglycerol lipase (MAGL) inhibitors, compositions and use thereof APOGEE PHARMACEUTICALS, INC. (CA) 2025-08-05 US claimed
EP-4419525-B1 HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER ARTIOS PHARMA LTD (GB) 2025-07-23 EP claimed
US-20250230165-A1 HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER ARTIOS PHARMA LIMITED (GB) 2025-07-17 US claimed
WO-2021028362-A1 SHP2 INHIBITORS IRBM S.P.A. (IT) 2021-02-18 WO claimed
EP-3772513-A1 SHP2 INHIBITORS C.N.C.C.S. S.c.a.r.l. Collezione Nazionale Dei Composti Chimici e Centro Screening (IT) 2021-02-10 EP claimed
US-20200291029-A1 CARBAPENEM COMPOUNDS MERCK SHARP & DOHME CORP. 2020-09-17 US claimed
WO-2020150474-A1 PCSK9 INHIBITORS AND METHODS OF USE THEREOF DOGMA THERAPEUTICS, INC. (US) 2020-07-23 WO claimed
WO-2020150473-A2 PCSK9 INHIBITORS AND METHODS OF USE THEREOF DOGMA THERAPEUTICS, INC. (US) 2020-07-23 WO claimed
US-10450273-B2 N-(pyridin-2-yl)pyridine-sulfonamide derivatives and their use in the treatment of disease NOVARTIS AG (CH) 2019-10-22 US claimed
EP-3504194-A1 N-(PYRIDIN-2-YL)PYRIDINE-SULFONAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE Novartis AG (CH) 2019-07-03 EP claimed
US-20180072673-A1 N-(pyridin-2-yl)pyridine-sulfonamide Derivatives and their Use in the Treatment of Disease NOVARTIS AG (CH) 2018-03-15 US claimed
WO-2018042316-A1 N-(PYRIDIN-2-YL)PYRIDINE-SULFONAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE NOVARTIS AG (CH) 2018-03-08 WO claimed
US-8680092-B2 Nitrogenous heterocyclic compound and medicinal use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2014-03-25 US claimed